GRI Bio Completes Successful Public Offering, Raising Funds for NKT Cell Modulators
LA JOLLA, CA – April 02, 2025
GRI Bio, Inc. (GRI), a pioneering biotechnology company, recently announced the successful completion of a public offering. This offering included the sale of 1,388,888 shares of common stock, as well as Series E-1, E-2, and E-3 warrants.
Details of the Offering
The offering price for each share of common stock and accompanying Series Warrants was set at $3.60. The Series Warrants consist of:
- Series E-1 warrants, with an exercise price of $3.20 per share and a five-year expiration date.
- Short-term Series E-2 warrants, with an exercise price of $3.20 per share and an eighteen-month expiration date.
- Short-term Series E-3 warrants, with an exercise price of $3.20 per share and a nine-month expiration date.
Implications for GRI Bio
GRI Bio will utilize the funds raised from this offering to advance its innovative pipeline of Natural Killer T (NKT) cell modulators. These treatments are designed for the treatment of various inflammatory, fibrotic, and autoimmune diseases. The successful completion of this public offering strengthens GRI’s financial position, enabling it to continue its research and development efforts and bring potentially life-changing therapies to market.
Impact on the World
The biotechnology industry, and more specifically the field of NKT cell modulation, stands to benefit from GRI Bio’s advancements. NKT cells play a crucial role in the immune system, and their manipulation could lead to groundbreaking treatments for various diseases. The successful funding of GRI Bio’s research efforts could pave the way for new therapies, improving the lives of countless individuals suffering from inflammatory, fibrotic, and autoimmune conditions.
Conclusion
GRI Bio’s recent public offering marks a significant milestone in the biotechnology industry, as the company continues to push the boundaries of NKT cell modulation. With the successful raising of funds, GRI Bio is well-positioned to advance its research efforts and bring potentially transformative therapies to market. The potential implications for individuals suffering from inflammatory, fibrotic, and autoimmune diseases are vast, and this development could revolutionize the way these conditions are treated.
As investors and industry observers continue to monitor GRI Bio’s progress, the future of NKT cell modulation and the biotechnology industry as a whole remains bright.
